A rapid microfluidic diagnostic assay for the measurement of Direct Oral Anticoagulants from patient whole blood
一种快速微流体诊断测定法,用于测量患者全血中的直接口服抗凝剂
基本信息
- 批准号:10482562
- 负责人:
- 金额:$ 122.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-01 至 2023-10-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAnticoagulantsAnticoagulationAntithrombin IIIAreaArrhythmiaAutomationBiological AssayBlindedBloodBlood CirculationBlood PlateletsBlood VesselsBlood coagulationBlood specimenCapitalCaringClassificationClinicClinicalClinical DataClinical ResearchCoagulation ProcessCollagen Type IComputer softwareCritical CareDataData SetDecision MakingDetectionDevelopmentDevicesDiagnosticDiseaseEmergency CareEventFDA approvedFibrinGoalsGoldHealth PersonnelHemophilia AHemorrhageHumanImageIn VitroInvestmentsJointsKnowledgeLaboratoriesLengthManualsMeasurementMeasuresMedicineMicrofluidic MicrochipsMicrofluidicsMonitorOperative Surgical ProceduresOralOutcomeOutcome AssessmentPatientsPennsylvaniaPerformancePharmaceutical PreparationsPhasePhysiciansPhysiologicalProcessProductionProteinsReagentReporterReproducibilityRiskRunningSafetySamplingSensitivity and SpecificitySignal TransductionSiteStrokeSystemTestingThrombinThromboplastinThrombosisTimeTraumaUniversitiesVariantWarfarinWhole BloodWorkanalytical methoddiagnostic assayevidence basehemodynamicsimprovedin vivoin-vitro diagnosticsinhibitorinnovationinstrumentmeetingsnovel strategiespatient populationpoint-of-care diagnosticsproduct developmentprograms
项目摘要
Abstract: Direct oral anticoagulants (DOACs) are becoming the preferred approach to managing
anticoagulation, particularly in thrombolytic disorders. DOAC use is anticipated to reach $30B globally in the next
five years, overtaking other anticoagulants such as warfarin. While highly effective, DOACs can elevate bleeding
risks, and complicate emergency care, which may include the use of expensive DOAC reversal agents. As current
diagnostics fail to adequately identify problems caused by DOACs, there exists growing safety concerns for this
class of drugs that are reinforced by the Joint Commission’s call for laboratory test monitoring, and evidence-
based approaches for safe DOAC, and reversal agent use. Whether treating a stroke/VTE/PE patient, heart
arrhythmia patient, or trauma/urgent surgery patient, the real-time determination of a patient’s state of
anticoagulation, including DOAC type (factor Xa inhibitor vs. direct thrombin inhibitor) is critical for rapid care
decisions to avoid adverse bleeding. A significant limitation of core laboratory detection of DOACs is the length
of time to results, which can exceed more than the typical 20-minute decision making window. FloBio is
developing the first DOAC in vitro diagnostic product to provide physicians with rapid knowledge of
anticoagulation state in emergency care settings. With our analyzer/imaging station, and disposable DOAC assay
cartridge/microfluidic device, our novel approach combines hemodynamic flow, and discrete clot activation, to
mimic physiological blood clotting. In less than 10 minutes, a healthcare provider will know a patient’s relative DOAC
concentration, and the DOAC classification.
FloBio’s Phase I work has demonstrated a scalable, multiplex, disposable DOAC assay cartridge/microfluidic
device that facilitates the natural blood clotting cascade in vitro, an instrument for measuring assay signals,
analytic software to provide the end user with a simple outcomes assessment, and clinical data that validates
the feasibility of the assay and device to detect DOAC class and level in human blood. FloBio’s innovation is a
diagnostic assay that will be the first in the market to provide real-time data on fibrin and platelet accumulation
on basal vascular and coagulation proteins, under flow, that recapitulates in vivo coagulation processes.
In Phase II, FloBio will focus on validating the DOAC assay in a 100 subject clinical study at the University of
Pennsylvania. This study will validate the capability of the assay to detect both class and DOAC level, within a
clinical patient population. A second clinical study with DOAC spiked healthy adult blood will determine the
device, assay and system range, sensitivity, specificity, variance, and consistency. Clinical assay data will be
validated against the gold standard of detection, LCMS. Automation of critical assay functions will also be
evaluated to reduce variation in the assay, and the feasibility of a fully integrated, automatable, disposable DOAC
assay cartridge will be demonstrated in healthy human blood samples. The outcome of the work will be a fully
vetted DOAC assay system that is ready for full development in Phase IIb.
翻译后摘要:直接口服抗凝剂(DOAC)正在成为首选的方法来管理
抗凝,特别是在血栓溶解性疾病中。DOAC的使用预计将达到300亿美元,在全球范围内,
五年,超过其他抗凝剂,如华法林。虽然非常有效,但DOAC可能会增加出血
风险和复杂的紧急护理,这可能包括使用昂贵的DOAC逆转剂。为流动
诊断无法充分识别由DOAC引起的问题,因此存在越来越多的安全问题
联合委员会呼吁进行实验室检测监测,这类药物得到了加强,
基于安全DOAC和逆转剂使用的方法。无论是治疗中风/VTE/PE患者,
例如,对于心律失常患者或创伤/紧急手术患者,实时确定患者的心律不齐状态是可能的。
抗凝治疗,包括DOAC类型(Xa因子抑制剂与直接凝血酶抑制剂)对于快速护理至关重要
避免不良出血的决定。核心实验室检测DOAC的一个重要限制是长度
这可能会超过典型的20分钟决策窗口。FloBio是
开发第一个DOAC体外诊断产品,为医生提供快速的知识,
在紧急护理环境中的抗凝状态。使用我们的分析仪/成像站和一次性DOAC检测
我们的新方法结合了血液动力学流动和离散凝块激活,
模拟生理性血液凝固。在不到10分钟的时间内,医疗保健提供者将知道患者的相对DOAC
浓度和DOAC分类。
FloBio的第一阶段工作已经证明了一种可扩展的、多路复用的、一次性的DOAC测定盒/微流体
促进体外自然凝血级联的装置,用于测量测定信号的仪器,
分析软件,为最终用户提供简单的结果评估和临床数据,
该测定法和装置检测人血液中DOAC类别和水平的可行性。FloBio的创新是
这是市场上第一个提供纤维蛋白和血小板聚集实时数据的诊断分析
基础血管和凝血蛋白,在流动下,重演体内凝血过程。
在第二阶段,FloBio将专注于验证DOAC检测在100名受试者的临床研究在大学
宾夕法尼亚本研究将验证该检测试剂盒在一年内检测类和DOAC水平的能力。
临床患者人群。使用DOAC掺入的健康成人血液的第二项临床研究将确定
器械、检测试剂盒和系统范围、灵敏度、特异性、方差和一致性。临床试验数据将
根据检测的金标准LCMS进行验证。关键检测功能的自动化也将
评估以减少测定中的变化,以及完全集成、可自动化、一次性DOAC的可行性
将在健康人血液样本中证明检测试剂盒。工作的结果将是一个全面的
经过审核的DOAC检测系统,已准备好在IIb期全面开发。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam Cuker其他文献
Adam Cuker的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam Cuker', 18)}}的其他基金
A rapid microfluidic diagnostic assay for the measurement of Direct Oral Anticoagulants from patient whole blood
一种快速微流体诊断测定法,用于测量患者全血中的直接口服抗凝剂
- 批准号:
10615908 - 财政年份:2019
- 资助金额:
$ 122.26万 - 项目类别:
Improving the diagnosis of heparin-induced thrombocytopenia
改善肝素诱导的血小板减少症的诊断
- 批准号:
8459944 - 财政年份:2012
- 资助金额:
$ 122.26万 - 项目类别:
Improving the diagnosis of heparin-induced thrombocytopenia
改善肝素诱导的血小板减少症的诊断
- 批准号:
8656424 - 财政年份:2012
- 资助金额:
$ 122.26万 - 项目类别:
Improving the diagnosis of heparin-induced thrombocytopenia
改善肝素诱导的血小板减少症的诊断
- 批准号:
8278801 - 财政年份:2012
- 资助金额:
$ 122.26万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 122.26万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 122.26万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 122.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 122.26万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 122.26万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 122.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 122.26万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 122.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 122.26万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 122.26万 - 项目类别:
Studentship Programs